Search

Your search keyword '"Geva, R."' showing total 191 results
Start Over Author "Geva, R." Publication Year Range Last 10 years
191 results on '"Geva, R."'

4. CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

Author

Armstrong, AJ, Geva, R, Chung, HC, Lemech, C, Miller Jr., WH, Hansen, AR, Lee, J-S, Tsai, F, Solomon, BJ, Kim, TM, Rolfo, C, Giranda, V, Ren, Y, Liu, F, Kandala, B, Freshwater, T, Wang, JS, Armstrong, AJ, Geva, R, Chung, HC, Lemech, C, Miller Jr., WH, Hansen, AR, Lee, J-S, Tsai, F, Solomon, BJ, Kim, TM, Rolfo, C, Giranda, V, Ren, Y, Liu, F, Kandala, B, Freshwater, T, and Wang, JS

Abstract

C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune checkpoint inhibitor efficacy. Preclinical evidence suggests potential benefit of CXCR2 inhibition in multiple solid tumors. In this phase 2 study (NCT03473925), adults with previously treated advanced or metastatic castration-resistant prostate cancer (CRPC), microsatellite-stable colorectal cancer (MSS CRC), or non-small-cell lung cancer (NSCLC) were randomized 1:1 to the CXCR2 antagonist navarixin 30 or 100 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks up to 35 cycles. Primary endpoints were investigator-assessed objective response rate (RECIST v1.1) and safety. Of 105 patients (CRPC, n=40; MSS CRC, n=40; NSCLC, n=25), 3 had a partial response (2 CRPC, 1 MSS CRC) for ORRs of 5%, 2.5%, and 0%, respectively. Median progression-free survival was 1.8-2.4 months without evidence of a dose-response relationship, and the study was closed at a prespecified interim analysis for lack of efficacy. Dose-limiting toxicities occurred in 2/48 patients (4%) receiving navarixin 30 mg and 3/48 (6%) receiving navarixin 100 mg; events included grade 4 neutropenia and grade 3 transaminase elevation, hepatitis, and pneumonitis. Treatment-related adverse events occurred in 70/105 patients (67%) and led to treatment discontinuation in 7/105 (7%). Maximal reductions from baseline in absolute neutrophil count were 44.5%-48.2% (cycle 1) and 37.5%-44.2% (cycle 2) and occurred within 6-12 hours postdose in both groups. Navarixin plus pembrolizumab did not demonstrate sufficient efficacy in this study. Safety and tolerability of the combination were manageable. (Trial registration: ClinicalTrials.gov , NCT03473925).

Published
2024

5. 161TiP A phase I/II, open-label study of an anti-ILT2 (LILRB1) antibody, SAR444881, administered alone and in combination with pembrolizumab, with or without chemotherapy, or cetuximab in patients with advanced solid tumors

Author

Perets, R., primary, Stemmer, S.M., additional, Geva, R., additional, Golan, T., additional, Fakih, M., additional, Cohen, J., additional, Lieu, C., additional, Jin, Z., additional, Lorusso, P., additional, Ashtamker, N., additional, Friedman, I., additional, Hakim, M., additional, Crawford, N., additional, Perez, R., additional, Agarwal, M., additional, Abbadessa, G., additional, Wu, M., additional, Lin, J., additional, Deantonio, C., additional, and Borad, M., additional

Published
2023
Full Text
View/download PDF

6. Comparing the Broad Socio-Cognitive Profile of Youth with Williams Syndrome and 22Q11.2 Deletion Syndrome

Author

Weisman, O., Feldman, R., Burg-Malki, M., Keren, M., Geva, R., Diesendruck, G., and Gothelf, D.

Abstract

Background: Numerous studies have assessed the socio-cognitive profile in Williams syndrome (WS) and, independently, in 22q11.2 deletion syndrome (22q11.2DS). Yet, a cross-syndrome comparison of these abilities between individuals with these two syndromes with known social deficits has not been conducted. Methods: Eighty-two children participated in four study groups: WS (n = 18), 22q112.DS (n = 24), age-matched individuals with idiopathic developmental disability (IDD; n = 20) and typically developing (TD) controls (n = 20). Participants completed four socio-cognitive tests: facial emotion recognition, mental state attribution, differentiating real from apparent emotions and trait inference based on motives and actions-outcomes. Results: The current findings demonstrate that children with WS were better in labelling happy faces compared with children with 22q11.2DS, partially reflecting their exaggerated social drive. In the false belief task, however, the WS and IDD groups performed poorly compared with the 22q11.2DS group, possibly due to their difficulty to interpret subtle social cues. When asked to identify the gap between real-negative vs. apparent-positive emotions, the 22q11.2DS group performed similarly to TD children but better than the WS group, possibly due to their anxious personality and their innate bias towards negatively valence cues. Finally, individuals with WS were more willing to become friends with a story character even when the character's motives were negative, reflecting their difficulty to avoid potentially harmful real-life situations. Conclusions: Overall, our multi-facet socio-cognitive battery uncovered strengths and weaknesses in social cognition that are syndrome-specific, shared among the genetic syndromes, or common to the three clinical groups compared with healthy controls. Our findings underscore the need to devise age-specific and condition-specific assessment tools and intervention programs towards improving these children's socio-cognitive deficits.

Published
2017
Full Text
View/download PDF

7. Long term durable effect of PectaSol-C Modified Citrus Pectin (P-MCP) treatment (tx) in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC-M0) patients (pts): Results of a prospective Phase II Study

Author

Keizman, D., primary, Frenkel, M., additional, Peer, A., additional, Kushnir, I., additional, Rosenbaum, E., additional, Sarid, D., additional, Leibovitch, I., additional, Mano, R., additional, Yossepowitch, O., additional, Margel, D., additional, Wolf, I., additional, Geva, R., additional, Rouvinov, K., additional, Dresler, H., additional, and Eliaz, I., additional

Published
2022
Full Text
View/download PDF

8. 990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

Author

Perets, R., Stemmer, S.M., Geva, R., Golan, T., Fakih, M., Cohen, J.E., Lieu, C., Jin, Z., Lorusso, P., Friedman, I., Hakim, M., Haves Ziv, D., Hashmueli, S., Mandel, I., Ben Moshe, T., Crawford, N., Abbadessa, G., Perez, R., Wu, M., and Borad, M.

Published
2024
Full Text
View/download PDF

10. P-81 Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1–positive metastatic colorectal cancer (mCRC)

Author

Kim, T., primary, Taieb, J., additional, Passhak, M., additional, Kim, T., additional, Kim, S., additional, Geva, R., additional, Hofsli, E., additional, Perl, G., additional, Yalcin, S., additional, Hubert, A., additional, Somer, B., additional, Wong, Z., additional, Wang, A., additional, Leconte, P., additional, Fogelman, D., additional, and Heinemann, V., additional

Published
2022
Full Text
View/download PDF

11. 476P Open-label phase I/II study evaluating the tolerability and antitumor activity of selinexor (SEL) and pembrolizumab (pembro) in colorectal cancer (CRC)

Author

Kutiel, T. Shentzer, primary, Golan, T., additional, Geva, R., additional, Gottfried, M., additional, Zick, A., additional, Shai, A., additional, Dudnik, J., additional, Netiv, E., additional, Yang, F., additional, Sharoni, S., additional, Meng, C., additional, Duic, P., additional, Michel, D., additional, Sbar, E., additional, Shah, J., additional, Kauffman, M.G., additional, Shacham, S., additional, and Zer, A., additional

Published
2021
Full Text
View/download PDF

12. 432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164

Author

Le, D.T., primary, Diaz, L., additional, Kim, T.W., additional, Van Cutsem, E., additional, Geva, R., additional, Jäger, D., additional, Hara, H., additional, Burge, M., additional, O'Neil, B., additional, Kavan, P., additional, Yoshino, T., additional, Guimbaud, R., additional, Taniguchi, H., additional, Elez, E., additional, Al-Batran, S-E., additional, Boland, P., additional, Cui, Y., additional, Leconte, P., additional, Marinello, P., additional, and André, T., additional

Published
2021
Full Text
View/download PDF

17. 524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours

Author

Siu, L.L., primary, Wang, D., additional, Hilton, J., additional, Geva, R., additional, Rasco, D., additional, Abraham, A.K., additional, Markensohn, J.F., additional, Suttner, L., additional, Siddiqi, S., additional, Altura, R.A., additional, and Maurice-Dror, C., additional

Published
2020
Full Text
View/download PDF

18. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Author

Hammel P., Kindler H. L., Reni M., Van Cutsem E., MacArulla T., Hall M. J., Park J. O., Hochhauser D., Arnold D., Oh D. -Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E. M., McGuinness D., Cui K. Y., Joo S., Yoo H. K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J. -L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J. -F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J. -P., Tougeron D., Walter T., Ettrich T., Hacker U. T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J. -W., Oh Park J., Wilmink H., Gallego R. A., Ogalla G. D., Velasco A. G., Cabanas E. G., Gomez Martin C., Ponce C. G., Saez B. L., Lopez R., Martin A. M., Pazo R., Pijaume C. P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D. A., Jeffrey Evans T. R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Hammel P., Kindler H.L., Reni M., Van Cutsem E., MacArulla T., Hall M.J., Park J.O., Hochhauser D., Arnold D., Oh D.-Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E.M., McGuinness D., Cui K.Y., Joo S., Yoo H.K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J.-L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J.-F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J.-P., Tougeron D., Walter T., Ettrich T., Hacker U.T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J.-W., Oh Park J., Wilmink H., Gallego R.A., Ogalla G.D., Velasco A.G., Cabanas E.G., Gomez Martin C., Ponce C.G., Saez B.L., Lopez R., Martin A.M., Pazo R., Pijaume C.P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D.A., Jeffrey Evans T.R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Institut Català de la Salut, [Hammel P] Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. [Kindler HL] Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA. [Reni M] Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology, Barcelona, Spain. [Hall MJ] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA, Vall d'Hebron Barcelona Hospital Campus, CCA - Cancer Treatment and Quality of Life, and Oncology

Subjects
Male, 0301 basic medicine, Oncology, medicine.medical_treatment, BRCA, pancreatic cancer, Disease, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Piperazines, Germline, Medicaments antineoplàstics, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Neoplasm Metastasis, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], BRCA1 Protein, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Middle Aged, Progression-Free Survival, humanities, 3. Good health, metastatic, health-related quality of life, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Poly(ADP-ribose) Polymerase Inhibitors, Placebo, olaparib, Olaparib, 03 medical and health sciences, Double-Blind Method, Metàstasi, Pancreatic cancer, Internal medicine, Gastrointestinal Tumors, medicine, Humans, Germ-Line Mutation, Aged, BRCA2 Protein, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], Chemotherapy, Pàncrees - Càncer, business.industry, BRCA mutation, Original Articles, medicine.disease, Pancreatic Neoplasms, Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], 030104 developmental biology, chemistry, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Quality of Life, Phthalazines, Neoplasm Recurrence, Local, business
Abstract

Qualitat de vida relacionada amb la salut; Olaparib; Càncer de pàncrees Calidad de vida relacionada con la salud; Olaparib, Cáncer de páncreas Health-related quality of life; Olaparib; Pancreatic cancer Background Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. Patients and methods Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. Results Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was

Published
2019

19. First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors

Author

Garralda, E. (Elena), Geva, R. (Ravit), Ben-Ami, E. (Eytan), Maurice-Dror, C. (Corinne), Calvo, E. (Emiliano), LoRusso, P. (Patricia), Türec, Ö. (Özlem), Niewood, M. (Michelle), Sahin, U. (Ugur), Jure-Kunkel, M. (María), Forssmann, U. (Ulf), Ahmadi, T. (Tahamtan), and Melero, I. (Ignacio)

Subjects
Cancer immunotherapies, T cells, Monotherapy
Abstract

Agonistic 4-1BB monoclonal antibodies were preclinically validated as promising cancer immunotherapies, both as monotherapy and as potentiators of the activity of PD-(L) 1–blocking agents. However, toxicity and a narrow therapeutic window have hampered their clinical development. DuoBodyPD-L1×4-1BB, a first-in-class, bispecific, next-generation checkpoint immunotherapy, was designed to overcome these limitations by activating T cells through conditional 4-1BB costimulation, while simultaneously blocking the PD-L1 axis. We present preliminary data from the ongoing, first-in-human, open-label, phase I/IIa trial of DuoBody-PD-L1×4-1BB in advanced solid tumors (NCT03917381).

Published
2020

21. Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III study by the GERCOR group

Author

André, T., primary, Vernerey, D., additional, Im, S.-A., additional, Bodoky, G.M., additional, Buzzoni, R., additional, Reingold, S., additional, Rivera, F., additional, McKendrick, J., additional, Scheithauer, W., additional, Geva, R., additional, Fountzilas, G., additional, Yong, W.P., additional, Isaacs, R., additional, Österlund, P., additional, Liang, J.-T., additional, Creemers, G.-J., additional, Van Cutsem, E., additional, Cunningham, D., additional, Tabernero, J., additional, and De Gramont, A., additional

Published
2019
Full Text
View/download PDF

22. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study

Author

O'Malley, D., primary, Marabelle, A., additional, De Jesus-Acosta, A., additional, Piha-Paul, S.A., additional, Arkhipov, A., additional, Longo, F., additional, Motola-Kuba, D., additional, Shapira-Frommer, R., additional, Geva, R., additional, Rimel, B.J., additional, Lopez-Martin, J.A., additional, Hansen, A.R., additional, Mehnert, J.M., additional, Chen, X., additional, Jin, F., additional, Norwood, K., additional, and Ott, P.A., additional

Published
2019
Full Text
View/download PDF

23. Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

Author

Diaz, L.A., primary, Le, D., additional, Maio, M., additional, Ascierto, P.A., additional, Geva, R., additional, Motola-Kuba, D., additional, André, T., additional, Van Cutsem, E., additional, Gottfried, M., additional, Elez, E., additional, Delord, J.-P., additional, Jäger, D., additional, Kim, T.W., additional, Guimbaud, R., additional, Yoshino, T., additional, Chen, M., additional, Norwood, K., additional, Marinello, P., additional, and Marabelle, A., additional

Published
2019
Full Text
View/download PDF

24. 40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH

Author

Fuchs, Cs, Doi, T, Jang, Rw, Muro, K, Satoh, T, Machado, M, Sun, W, Jalal, Si, Shah, Ma, Metges, Jp, Garrido, M, Golan, T, Mandala', M, Wainberg, Za, Catenacci, Dv, Ohtsu, A, Shitara, K, Geva, R, Bleeker, J, Ko, Ah, Ku, G, Philip, P, Enzinger, Pc, Bang, Yj, Levitan, D, Wang, J, Rosales, M, Dalal, Rp, and Yoon, Hh.

Published
2018

25. A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)

Author

Hidalgo, M., primary, Epelbaum, R., additional, Wolpin, B.M., additional, Stemmer, S.M., additional, Geva, R., additional, Golan, T., additional, Borazanci, E., additional, Borad, M., additional, Pedersen, K.S., additional, Park, J.O., additional, Ramirez, R., additional, Peled, A., additional, Lustig, T.M., additional, Bohana Kashtan, O., additional, Rosenfeld, O., additional, Sorani, E., additional, Schlienger, K., additional, Vainstein Haras, A., additional, and Von Hoff, D.D., additional

Published
2018
Full Text
View/download PDF

26. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164

Author

Le, D., primary, Kavan, P., additional, Kim, T., additional, Burge, M., additional, Van Cutsem, E., additional, Hara, H., additional, Boland, P., additional, Van Laethem, J., additional, Geva, R., additional, Taniguchi, H., additional, Crocenzi, T., additional, Sharma, M., additional, Atreya, C., additional, Diaz, L., additional, Liang, L., additional, Marinello, P., additional, Dai, T., additional, and O’Neill, B., additional

Published
2018
Full Text
View/download PDF

28. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies.

Author

Helmberger T., Findlay M.P.N., Isaacs R., O'Donnell A., Perez D., Rodriguez J., Vera-Garcia R., Amin P., Bloomgarden D., Bui J., Carlisle J., Chai S., Chen Y.-J., Chuong M., Coveler A., Facchini F., Frenette G., Frick J., Garofalo M., George B., Gordon M., Gulec S., Hannigan J., Holtzman M., Kaubisch A., Kaiser A., Kooy T., Limentani S., Margolis J., Martin R., Ozer H., Padia S., Rilling W., Savin M., Schneiderman E., Seeger G., Shibata S., Smith R., Wang E., Whiting S., Aghmesheh M., Cooray P., Feeney K., Lim L., Singh M., Underhill C., Durand A., Faivre S., Ferru A., Hammel P., Bremer C., De Wit M., Ayala H., Heching N., Shani A., Granetto C., Masi G., Mosconi S., Numico G., Trogu A., Kim Y.H., Sae-Won H., Fragoso M., Tan I., Casado A.R., Liang J.T., Liu J.H., Ades S., Auber M., Boland P., Bowers C., Crain M., Dowling K., Iyer R., Ratner L., Sanchez F., Stoltzfus P., Westcott M., Segelov E., Strickland A., Gibbs P., Heinemann V., Sharma N., Taieb J., Ricke J., Peeters M., Robinson B.A., Jackson C., Gebski V., Van Buskirk M., Zhao H., van Hazel G., Brown M., Burge M., Cardaci G., Clarke S., Eliadis P., Ferguson T., Ganju V., James P., Karapetis C., Liauw W., Marx G., Matos M., Nott L., Pavlakis N., Powell A., Price T., Ransom D., Shannon J., Singhal N., Walpole E., Craninx M., Delaunoit T., Deleporte A., Ferrante M., Geboes K., Hendlisz A., Hendrickx K., De Man M., Monsaert E., Moons V., Polus M., Boucher E., Balosso J., Chevallier P., Louafi S., Pracht M., Rebischung C., Smith D., Terrebonne E., Bruch H.-R., Gehbauer G., Ko Y.-D., Kroning H., Lammert F., Nusch A., Pluntke S., Ridwelski K., Riera-Knorrenschild J., Riess H., Riera J.R., Sauerbruch T., Scheidhauer K., Stotzer O., Tatsch K., Vehling-Kaiser U., Vogl T., Beny A., Geva R., Shacham-Shmueli E., Stemmer S., Tichler T., Wolf I., Angelelli B., Martoni A., Helmberger T., Findlay M.P.N., Isaacs R., O'Donnell A., Perez D., Rodriguez J., Vera-Garcia R., Amin P., Bloomgarden D., Bui J., Carlisle J., Chai S., Chen Y.-J., Chuong M., Coveler A., Facchini F., Frenette G., Frick J., Garofalo M., George B., Gordon M., Gulec S., Hannigan J., Holtzman M., Kaubisch A., Kaiser A., Kooy T., Limentani S., Margolis J., Martin R., Ozer H., Padia S., Rilling W., Savin M., Schneiderman E., Seeger G., Shibata S., Smith R., Wang E., Whiting S., Aghmesheh M., Cooray P., Feeney K., Lim L., Singh M., Underhill C., Durand A., Faivre S., Ferru A., Hammel P., Bremer C., De Wit M., Ayala H., Heching N., Shani A., Granetto C., Masi G., Mosconi S., Numico G., Trogu A., Kim Y.H., Sae-Won H., Fragoso M., Tan I., Casado A.R., Liang J.T., Liu J.H., Ades S., Auber M., Boland P., Bowers C., Crain M., Dowling K., Iyer R., Ratner L., Sanchez F., Stoltzfus P., Westcott M., Segelov E., Strickland A., Gibbs P., Heinemann V., Sharma N., Taieb J., Ricke J., Peeters M., Robinson B.A., Jackson C., Gebski V., Van Buskirk M., Zhao H., van Hazel G., Brown M., Burge M., Cardaci G., Clarke S., Eliadis P., Ferguson T., Ganju V., James P., Karapetis C., Liauw W., Marx G., Matos M., Nott L., Pavlakis N., Powell A., Price T., Ransom D., Shannon J., Singhal N., Walpole E., Craninx M., Delaunoit T., Deleporte A., Ferrante M., Geboes K., Hendlisz A., Hendrickx K., De Man M., Monsaert E., Moons V., Polus M., Boucher E., Balosso J., Chevallier P., Louafi S., Pracht M., Rebischung C., Smith D., Terrebonne E., Bruch H.-R., Gehbauer G., Ko Y.-D., Kroning H., Lammert F., Nusch A., Pluntke S., Ridwelski K., Riera-Knorrenschild J., Riess H., Riera J.R., Sauerbruch T., Scheidhauer K., Stotzer O., Tatsch K., Vehling-Kaiser U., Vogl T., Beny A., Geva R., Shacham-Shmueli E., Stemmer S., Tichler T., Wolf I., Angelelli B., and Martoni A.

Abstract

The primary tumor side is emerging as a prognostic factor for patients with liver metastatic colorectal cancer (mCRC). In a combined analysis of data from 2 randomized studies, the addition of selective internal radiation therapy to first-line chemotherapy in patients with mCRC was associated with statistically and clinically significant overall survival gains for patients with a right-sided primary tumor. Background(s): The primary tumor side is emerging as a major prognostic factor for patients with metastatic colorectal cancer (mCRC). We examined the survival data from 2 randomized studies to determine whether the outcomes differ between patients with mCRC with right-sided primary (RSP) tumors and those with left-sided primary (LSP) tumors after selective internal radiation therapy (SIRT) plus mFOLFOX6 (folinic acid [leucovorin], 5-fluorouracil, oxaliplatin) chemotherapy, versus chemotherapy alone. Patients and Methods: Separate and combined analyses were performed on the data from the SIRFLOX and FOXFIRE global trials, which compared chemotherapy plus SIRT with chemotherapy alone for patients with mCRC liver metastases. The primary tumor side data were prospectively collected. The principal outcome measure was overall survival (OS) stratified by treatment and primary tumor side. Result(s): In the combined analysis of all 739 patients enrolled, SIRT had no effect on OS (median OS, 24.3 vs. 24.6 months; hazard ratio [HR], 1.021; P =.810). For the 179 patients (24.2%) with a RSP tumor, OS was improved with the addition of SIRT (median, 22.0 vs. 17.1 months HR, 0.641; P =.008). The addition of SIRT was not associated with a significant difference in OS among the 540 patients with a LSP tumor (median, 24.6 vs. 26.6 months; HR, 1.120; P =.264). A test of treatment interaction by primary tumor side was statistically significant for RSP and SIRT (P =.002). Conclusion(s): The addition of SIRT for patients with RSP tumors, but not for those with LSP tumors, was associated

Published
2018

31. Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers

Author

Diaz, L., primary, Marabelle, A., additional, Kim, T.W., additional, Geva, R., additional, Van Cutsem, E., additional, André, T., additional, Ascierto, P.A., additional, Maio, M., additional, Delord, J-P., additional, Gottfried, M., additional, Guimbaud, R., additional, Jaeger, D., additional, Elez, E., additional, Yoshino, T., additional, Joe, A., additional, Lam, B., additional, Ding, J., additional, Pruitt, S., additional, Kang, S.P., additional, and Le, D.T., additional

Published
2017
Full Text
View/download PDF

34. KEYNOTE-059 Update: Efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal (G/GEJ) cancer

Author

Wainberg, Z.A., primary, Jalal, S., additional, Muro, K., additional, Yoon, H.H., additional, Garrido, M., additional, Golan, T., additional, Doi, T., additional, Catenacci, D.V., additional, Geva, R., additional, Ku, G., additional, Bleeker, J., additional, Bang, Y-J., additional, Hara, H., additional, Chung, H.C., additional, Savage, M., additional, Wang, J., additional, Koshiji, M., additional, Dalal, R., additional, and Fuchs, C.S., additional

Published
2017
Full Text
View/download PDF

37. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010

Author

Van Cutsem, E., Dicato, M., Geva, R., Arber, N., Bang, Y., Benson, A., Cervantes, A., Diaz-Rubio, E., Ducreux, M., Glynne-Jones, R., Grothey, A., Haller, D., Haustermans, K., Kerr, D., Nordlinger, B., Marshall, J., Minsky, B. D., Kang, Y. K., Labianca, R., Lordick, F., Ohtsu, A., Pavlidis, N., Roth, A., Rougier, P., Schmoll, H. J., Sobrero, A., Tabernero, J., Van de Velde, C., Zalcberg, J., Van Cutsem, E., Dicato, M., Geva, R., Arber, N., Bang, Y., Benson, A., Cervantes, A., Diaz-Rubio, E., Ducreux, M., Glynne-Jones, R., Grothey, A., Haller, D., Haustermans, K., Kerr, D., Nordlinger, B., Marshall, J., Minsky, B. D., Kang, Y. K., Labianca, R., Lordick, F., Ohtsu, A., Pavlidis, N., Roth, A., Rougier, P., Schmoll, H. J., Sobrero, A., Tabernero, J., Van de Velde, C., and Zalcberg, J.

Abstract

Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on the diagnosis and management of patients with gastric cancer. This article summarizes the recommendations and expert opinion on gastric cancer. It discusses and reflects on the regional differences in the incidence and care of gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents the latest recommendations in the staging and treatment of primary and metastatic gastric cancer. Recognition is given to the need for larger and well-designed clinical trials to answer many open questions

Published
2017

44. Brain plasticity following intensive bimanual therapy in children with hemiplegia

Author

Weinstein, M, Myers, V, Green, D, Schertz, M, Shiran, S, Geva, R, Artzi, M, Gordon, A, Fattal-Valevski, A, Bashat, D, Weinstein, M, Myers, V, Green, D, Schertz, M, Shiran, S, Geva, R, Artzi, M, Gordon, A, Fattal-Valevski, A, and Bashat, D

Abstract

Neuroplasticity studies examining children with hemiparesis (CH) have focused predominantly on unilateral interventions. CH also have bimanual coordination impairments with bimanual interventions showing benefits. We explored neuroplasticity following hand-arm bimanual intensive therapy (HABIT) of 60 hours in twelve CH (6 females, mean age 11 ± 3.6 y). Serial behavioral evaluations and MR imaging including diffusion tensor (DTI) and functional (fMRI) imaging were performed before, immediately after, and at 6-week follow-up. Manual skills were assessed repeatedly with the Assisting Hand Assessment, Children’s Hand Experience Questionnaire, and Jebsen-Taylor Test of Hand Function. Beta values, indicating the level of activation, and lateralization index (LI), indicating the pattern of brain activation, were computed from fMRI. White matter integrity of major fibers was assessed using DTI. 11/12 children showed improvement after intervention in at least one measure, with 8/12 improving on two or more tests. Changes were retained in 6/8 children at follow-up. Beta activation in the affected hemisphere increased at follow-up, and LI increased both after intervention and at follow-up. Correlations between LI and motor function emerged after intervention. Increased white matter integrity was detected in the corpus callosum and corticospinal tract after intervention in about half of the participants. Results provide first evidence for neuroplasticity changes following bimanual intervention in CH.

Published
2015

45. Brain Plasticity following Intensive Bimanual Therapy in Children with Hemiparesis : Preliminary Evidence

Author

Weinstein, M., Myers, V., Green, Dido, Schertz, M., Shiran, S. I., Geva, R., Artzi, M., Gordon, A. M., Fattal-Valevski, A., Ben Bashat, D., Weinstein, M., Myers, V., Green, Dido, Schertz, M., Shiran, S. I., Geva, R., Artzi, M., Gordon, A. M., Fattal-Valevski, A., and Ben Bashat, D.

Abstract

Neuroplasticity studies examining children with hemiparesis (CH) have focused predominantly on unilateral interventions. CH also have bimanual coordination impairments with bimanual interventions showing benefits. We explored neuroplasticity following hand-Arm bimanual intensive therapy (HABIT) of 60 hours in twelve CH (6 females, mean age 11 ± 3.6 y). Serial behavioral evaluations and MR imaging including diffusion tensor (DTI) and functional (fMRI) imaging were performed before, immediately after, and at 6-week follow-up. Manual skills were assessed repeatedly with the Assisting Hand Assessment, Children's Hand Experience Questionnaire, and Jebsen-Taylor Test of Hand Function. Beta values, indicating the level of activation, and lateralization index (LI), indicating the pattern of brain activation, were computed from fMRI. White matter integrity of major fibers was assessed using DTI. 11/12 children showed improvement after intervention in at least one measure, with 8/12 improving on two or more tests. Changes were retained in 6/8 children at follow-up. Beta activation in the affected hemisphere increased at follow-up, and LI increased both after intervention and at follow-up. Correlations between LI and motor function emerged after intervention. Increased white matter integrity was detected in the corpus callosum and corticospinal tract after intervention in about half of the participants. Results provide first evidence for neuroplasticity changes following bimanual intervention in CH.

Published
2015
Full Text
View/download PDF

46. LBA-04 Clinical outcomes and their correlation with gene expression in patients with advanced gastric cancer treated with pembrolizumab (MK-3475): KEYNOTE-012

Author

Bang, Y-J., primary, Chung, H.C., additional, Shankaran, V., additional, Geva, R., additional, Catenacci, D., additional, Gupta, S., additional, Eder, J.P., additional, Berger, R., additional, Emancipator, K., additional, Pathiraja, K., additional, McClanahan, T., additional, Ayers, M., additional, Lunceford, J., additional, Cheng, J., additional, Koshiji, M., additional, and Muro, K., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results